MTOR and acute myeloid leukemia: The investigators then demonstrated that the PI3K/mTOR pathway is indeed activated by parthenolide using a biochemical approach and that there is synergism with PI3K and mTOR inhibitors in combination with parthenolide in vitro and with the pharmacologically superior analogue dimethyl-amino-parthenolide in primary human AML orthotopic models.